西亚试剂：Modelling pathogenesis and treatment of familial dysautonom

发布时间：2025-06-10

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

Gabsang Lee1, Eirini P. Papapetrou2, Hyesoo Kim1, Stuart M. Chambers1, Mark J. Tomishima1,2,3, Christopher A. Fasano1, Yosif M. Ganat1,6, Jayanthi Menon4, Fumiko Shimizu4, Agnes Viale5, Viviane Tabar2,4, Michel Sadelain2 & Lorenz Studer1,2,4

1 Developmental Biology Program,
2 Center for Cell Engineering,
3 SKI Stem Cell Research Facility,
4 Department of Neurosurgery,
5 Genomics Core Facility, Sloan-Kettering Institute, 1275 York Ave,
6 Weill Cornell Graduate School, New York, New York 10065, USA

The isolation of human induced pluripotent stem cells (iPSCs)1, 2, 3 offers a new strategy for modelling human disease. Recent studies have reported the derivation and differentiation of disease-specific human iPSCs4, 5, 6, 7. However, a key challenge in the field is the demonstration of disease-related phenotypes and the ability to model pathogenesis and treatment of disease in iPSCs. Familial dysautonomia (FD) is a rare but fatal peripheral neuropathy, caused by a point mutation in the IKBKAP 8 gene involved in transcriptional elongation9. The disease is characterized by the depletion of autonomic and sensory neurons. The specificity to the peripheral nervous system and the mechanism of neuron loss in FD are poorly understood owing to the lack of an appropriate model system. Here we report the derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons. Gene expression analysis in purified FD-iPSC-derived lineages demonstrates tissue-specific mis-splicing of IKBKAP in vitro. Patient-specific neural crest precursors express particularly low levels of normal IKBKAP transcript, suggesting a mechanism for disease specificity. FD pathogenesis is further characterized by transcriptome analysis and cell-based assays revealing marked defects in neurogenic differentiation and migration behaviour. Furthermore, we use FD-iPSCs for validating the potency of candidate drugs in reversing aberrant splicing and ameliorating neuronal differentiation and migration. Our study illustrates the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.

以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询
相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC 1,3,5-三氯苯 1,2,4-三氯苯 1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠 3-氨基苯硫酚 2,6-二氯苯硫酚 2,4-二氯苯硫酚 2,5-二氯苯硫酚 2-甲氧基苯硫酚 2-氯乙醇等均有销售.欢迎订购

上一篇：西亚试剂：科学家证实细胞线粒体基因病变导致衰老
下一篇：亚洲炼油产能2017年将达到三年来最高水平